Skip to main content

Table 1 Clinical and demographic features of TLE(HS) patients

From: Hippocampal gene expression dysregulation of Klotho, nuclear factor kappa B and tumor necrosis factor in temporal lobe epilepsy patients

Patients Gender Age (years) Side of HS Duration (years) Last seizure (days before surgery) TLE form AED during surgery
TLE 01 F 34.6 L 28.6 nd Familial PHT
TLE 02 F 29.1 L 22.1 2 Sporadic CBZ
TLE 03 F 23.8 R 22.3 7 Sporadic CBZ
TLE 04 M 42.8 R 41.2 3 Sporadic CBZ
TLE 05 M 41.2 L 34.2 5 Sporadic CBZ
TLE 06 M 50.8 R 48.8 7 Sporadic CBZ
TLE 07 M 12.7 L 9.7 3 Sporadic CBZ, PHT
TLE 08 F 43.8 B(L)a 41.8 nd Sporadic CBZ, LTG
TLE 09 F 58.2 R 57.7 nd Sporadic OXC, VPA
TLE 10 F 54.9 L 50.9 nd Sporadic CBZ
TLE 11 F 32.1 L 31.6 nd Familial CBZ
TLE 12 F 38.3 L 37.0 2 Familial OXC
TLE 13 F 54.1 L 53.3 nd Sporadic OXC, PHT
TLE 14 M 34.4 R 34.2 nd Familial OXC
  1. aThe hippocampal side was more affected when bilateral. When the patient’s last seizure was ‘nd’, the seizure most likely occurred over 7 days prior to surgery. TLE(HS), temporal lobe epilepsy associated with hippocampal sclerosis; M, male; F, female; B, bilateral; R, right; L, left; nd, not determined; AED, antiepileptic drug; CBZ, carbamazepine; PHT, phenytoin; OXC, oxcarbazepine; LTG, lamotrigine; VPA, valproate.